Moreover, it suggests that AR-targeted vaccines could be integrated into existing therapeutic regimens, potentially enhancing overall treatment efficacy for prostate cancer patients in a metastatic setting, as well as after an early diagnosis. The gene discussed is AR; the disease is prostate carcinoma.